Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
RaQualia Expands Alliance with HK inno.N, Licenses Japan Rights to Reflux Therapy
RaQualia Pharma said on December 12 that its board has approved an expansion of its capital and business alliance with South Korea’s HK inno.N, including a plan to license the Japanese rights to its gastric acid reducer tegoprazan. Under the…
To read the full story
Related Article
- RaQualia Partner Files US NDA for Tegoprazan
January 14, 2026
- RaQualia’s Reflux Therapy Tegoprazan Debuts in India
September 18, 2025
- RaQualia’s Acid Reducer Now Available in 5 Latin American Countries
December 13, 2024
- RaQualia’s Acid Reducer Tegoprazan Approved in Malaysia
September 27, 2024
- RaQualia’s Acid Reducer Tegoprazan Approved in Colombia
September 3, 2024
- RaQualia’s Acid Reducer Tegoprazan Now Available in Singapore
September 5, 2023
- RaQualia’s Acid Reducer Tegoprazan Launched in Indonesia
July 12, 2023
- RaQualia’s Acid Reducer Tegoprazan Approved in Singapore
January 16, 2023
- RaQualia’s Acid Reducer Tegoprazan Now Available in China
May 10, 2022
BUSINESS
- Nippon Kayaku Aims to Lift New Drug Sales Ratio to 30%, Bolsters Oncology Push
February 25, 2026
- Keio Spinoff Taps Nikon as CDMO, Targets 2027 Start for KP8011 Trial
February 25, 2026
- Astellas, Vir Strike Strategic Deal to Advance PSMA-Targeting TCE
February 25, 2026
- Nippon Shinyaku to Take Over UCB’s Fintepla in Japan from April
February 25, 2026
- Opdivo-Yervoy Expands Label for Colorectal Cancer in South Korea
February 25, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…